RxDoctor Payments Data

Yogesh Vohra, MD

Internal Medicine · Salisbury, MDNPI 1598785412

Payments from drug & device makers

$4,711in general payments, 2019–2025

Across 270 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$689
  • Lilly USA, LLC$462
  • Pfizer$419
  • Novo Nordisk$398
  • Amgen$337
  • AstraZeneca$308
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,711100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,711 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$920,228
Medicare patients
1,585
Services billed
9,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$235,001
EliquisApixaban276$188,425
MounjaroTirzepatide130$151,526
JardianceEmpagliflozin122$105,851
LinzessLinaclotide116$72,700
JanuviaSitagliptin Phosphate85$55,807
XareltoRivaroxaban71$50,565
VraylarCariprazine Hcl11$31,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$28,955
TrulicityDulaglutide18$28,706
CreonLipase/Protease/Amylase39$26,586
ProliaDenosumab16$26,287
TradjentaLinagliptin41$25,807
VelphoroSucroferric Oxyhydroxide15$25,805
Breo ElliptaFluticasone/Vilanterol56$24,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$398$235,001217 claims
PfizerEliquis$419$188,425276 claims
Lilly USA, LLCMounjaro, Trulicity$462$180,232148 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Glyxambi$144$161,909200 claims
AbbVieLinzess, Vraylar, Creon, Ubrelvy, Qulipta$689$161,770188 claims
MerckJanuvia, Belsomra, Janumet$14$74,584119 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$57$61,06999 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$308$54,92193 claims
Johnson & JohnsonXarelto$174$50,56571 claims
AmgenProlia$337$26,28716 claims
NovartisEntresto$87$23,89020 claims
Astellas Pharma US IncMyrbetriq$141$13,82926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →